A Prospective Multicenter Clinical Observational Study on Vancomycin Efficiency and Safety With Therapeutic Drug...

Area of Science:

• Pharmacology
• Infectious Diseases
• Clinical Pharmacy

Background:

• Vancomycin is a critical antibiotic for severe gram-positive bacterial infections.
• Current guidelines suggest vancomycin trough concentrations of 10-15 mg/L for regular infections and 15-20 mg/L for severe infections.
• The study aimed to evaluate higher vancomycin concentrations in the Chinese population.

Purpose of the Study:

• To determine if increasing vancomycin trough concentration improves clinical outcomes in Chinese patients.
• To assess the safety and adverse effects of higher vancomycin concentrations.
• To identify optimal vancomycin trough concentration thresholds for efficacy and safety.

Main Methods:

• A prospective, open-label, multicenter observational study.
• Inclusion of 510 patients with gram-positive bacterial infections across 13 hospitals.
• Collection of clinical, microbiological, and laboratory data, including vancomycin therapeutic drug monitoring.

Main Results:

• Of 470 evaluable patients, 35.53% had MRSA and 23.19% had Enterococcus infections.
• Average vancomycin trough concentrations were 10.54 ± 8.08 mg/L in adults and 6.74 ± 8.93 mg/L in children.
• No correlation found between vancomycin trough concentration and clinical outcomes (P > .05).
• Vancomycin trough concentration was correlated with nephrotoxicity in adults (P < .0001), with an applicable cut-off at 13 mg/L.
• Infection eradication rates were high: 86.22% in adults and 96% in children.
• No severe adverse events or deaths were attributed to vancomycin.

Conclusions:

• Vancomycin trough concentration is not statistically correlated with clinical outcomes in the studied Chinese population.
• Vancomycin trough concentration serves as an indicator for nephrotoxicity.
• Increasing vancomycin trough concentration to 15-20 mg/L offers no demonstrated benefit for Chinese patients with complicated infections.